Compare Stocks: OKUR, PRTC, RZLT, and ARCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.74 +6.8%	$12.75	$5.50 ▼ $24.17	$365.80M	2.48	821,257 shs	675,624 shs
OKUR OnKure Therapeutics	$2.41 +4.8%	$3.39	$2.13 ▼ $5.38	$92.91M	0.12	386,949 shs	609,203 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A
RZLT Rezolute	$4.87 +5.0%	$4.46	$1.07 ▼ $11.46	$448.82M	0.53	1.83 million shs	1.87 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+0.78%	-2.57%	-17.66%	+84.65%	-39.29%
OKUR OnKure Therapeutics	-2.13%	-9.45%	-32.35%	-46.26%	-24.34%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	-7.17%
RZLT Rezolute	+5.94%	+14.00%	+5.45%	-2.32%	-46.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.74 +6.8%	$12.75	$5.50 ▼ $24.17	$365.80M	2.48	821,257 shs	675,624 shs
OKUR OnKure Therapeutics	$2.41 +4.8%	$3.39	$2.13 ▼ $5.38	$92.91M	0.12	386,949 shs	609,203 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A
RZLT Rezolute	$4.87 +5.0%	$4.46	$1.07 ▼ $11.46	$448.82M	0.53	1.83 million shs	1.87 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+0.78%	-2.57%	-17.66%	+84.65%	-39.29%
OKUR OnKure Therapeutics	-2.13%	-9.45%	-32.35%	-46.26%	-24.34%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	-7.17%
RZLT Rezolute	+5.94%	+14.00%	+5.45%	-2.32%	-46.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.67	Moderate Buy	$22.00	60.12% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	626.14% Upside
PRTC PureTech Health	1.00	Sell	N/A	N/A
RZLT Rezolute	2.79	Moderate Buy	$11.22	130.44% Upside

Current Analyst Ratings Breakdown

Latest OKUR, PRTC, RZLT, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $19.00
10/6/2026	RZLT Rezolute	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $12.00
10/6/2026	RZLT Rezolute	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
10/6/2026	RZLT Rezolute	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$11.00 ➝ $15.00
10/5/2026	RZLT Rezolute	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
9/30/2026	RZLT Rezolute	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
9/29/2026	RZLT Rezolute	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$4.00 ➝ $7.00
9/25/2026	RZLT Rezolute	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy
9/25/2026	RZLT Rezolute	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $10.00
9/24/2026	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	4.76	N/A	N/A	$7.53 per share	1.82
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
PRTC PureTech Health	$4.66M	91.01	N/A	N/A	$12.65 per share	1.38
RZLT Rezolute	N/A	N/A	N/A	N/A	$1.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)
PRTC PureTech Health	-$109.74M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	-$77.59M	-$0.76	N/A	N/A	N/A	N/A	-62.99%	-57.94%	11/5/2026 (Estimated)

Latest OKUR, PRTC, RZLT, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	OKUR OnKure Therapeutics	-$0.36	N/A	N/A	N/A	$0.17 million	N/A
11/5/2026	Q1 2027	RZLT Rezolute	-$0.18	N/A	N/A	N/A	$1.12 million	N/A
9/24/2026	Q4 2026	RZLT Rezolute	-$0.1479	-$0.20	-$0.0522	-$0.20	N/A	N/A
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
OKUR OnKure Therapeutics	N/A	26.75	26.75
PRTC PureTech Health	N/A	6.59	6.59
RZLT Rezolute	N/A	9.68	9.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
OKUR OnKure Therapeutics	90.98%
PRTC PureTech Health	0.04%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
OKUR OnKure Therapeutics	2.17%
PRTC PureTech Health	5.30%
RZLT Rezolute	14.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
OKUR OnKure Therapeutics	45	40.40 million	39.52 million	N/A
PRTC PureTech Health	100	24.34 million	23.05 million	Not Optionable
RZLT Rezolute	58	96.73 million	82.43 million	Optionable

OKUR, PRTC, RZLT, and ARCT Headlines

Recent News About These Companies

Rezolute, Inc. (RZLT) Latest Press Releases & Corporate News - Yahoo Finance

October 8 at 6:40 PM | finance.yahoo.com

Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

October 8 at 6:00 AM | defenseworld.netD

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Moderate Buy" from Analysts

October 8 at 4:29 AM | americanbankingnews.com

Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

October 8 at 4:28 AM | marketbeat.com

Cantor Fitzgerald upgrades Rezolute to overweight from neutral

October 6 at 4:20 PM | msn.com

Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug

October 6 at 4:20 PM | msn.com

Rezolute (NASDAQ:RZLT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

October 6 at 9:18 AM | americanbankingnews.com

Rezolute (NASDAQ:RZLT) Stock Price Target Raised at Citizens Jmp

October 6 at 9:17 AM | marketbeat.com

Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment

October 5, 2026 | finance.yahoo.com

Rezolute gets FDA nod for pre-BLA meeting despite phase 3 miss — retail expects huge rerating

October 5, 2026 | msn.com

Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying

October 5, 2026 | marketbeat.com

Rezolute Prepares For Potential BLA Filing Of Ersodetug In Congenital HI

October 5, 2026 | rttnews.com

Rezolute receives FDA guidance for ersodetug pre-BLA meeting

October 5, 2026 | grafa.comG

FDA Recommends Next Regulatory Step For Rezolute's Ersodetug;Stock Up

October 5, 2026 | rttnews.com

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

October 5, 2026 | globenewswire.com

Rezolute consensus price target increased by 18.70% to $9.28

October 2, 2026 | msn.com

Lake Street Capital Initiates Coverage on Rezolute (NASDAQ:RZLT)

October 2, 2026 | americanbankingnews.com

Rezolute (NASDAQ:RZLT) Raised to "Buy" at Craig Hallum

October 1, 2026 | americanbankingnews.com

Rezolute (NASDAQ:RZLT) Coverage Initiated by Analysts at Lake Street Capital

September 30, 2026 | marketbeat.com

Craig-Hallum upgrades Rezolute to buy from hold

September 29, 2026 | msn.com

Rezolute (NASDAQ:RZLT) Upgraded at Craig Hallum

September 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, PRTC, RZLT, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.74 +0.87 (+6.76%)

Closing price 04:00 PM Eastern

Extended Trading

$13.52 -0.22 (-1.56%)

As of 07:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

OnKure Therapeutics NASDAQ:OKUR

$2.41 +0.11 (+4.78%)

Closing price 04:00 PM Eastern

Extended Trading

$2.41 0.00 (0.00%)

As of 06:09 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)

As of 10/8/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Rezolute NASDAQ:RZLT

$4.87 +0.23 (+4.96%)

Closing price 04:00 PM Eastern

Extended Trading

$4.87 +0.00 (+0.06%)

As of 07:56 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, PRTC, RZLT, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, PRTC, RZLT, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, PRTC, RZLT, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, PRTC, RZLT, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

OnKure Therapeutics NASDAQ:OKUR

PureTech Health NASDAQ:PRTC

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OKUR, PRTC, RZLT, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OKUR, PRTC, RZLT, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OKUR, PRTC, RZLT, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR, PRTC, RZLT, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

OnKure Therapeutics NASDAQ:OKUR

PureTech Health NASDAQ:PRTC

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools